Abstract

Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4+ and CD8+ T cells enhance CD8+ T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8+ T-cell infiltration. We further show that SEMA3A affects CD8+ T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8+ T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.

Interactions between Semaphorin-3A (SEMA3A) and Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 have been shown to affect T cell development. Here the authors investigate how these interactions affect CD8+ T cells in tumour immunity, showing that NRP-1, Plexin-A1 and Plexin-A4 are upregulated on T cells allowing tumour derived SEMA3A to inhibit CD8+ T cell migration and function.

Details

Title
Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells
Author
Barnkob, Mike B. 1   VIAFID ORCID Logo  ; Michaels, Yale S. 2   VIAFID ORCID Logo  ; André, Violaine 3 ; Macklin, Philip S. 4   VIAFID ORCID Logo  ; Gileadi, Uzi 3   VIAFID ORCID Logo  ; Valvo, Salvatore 5   VIAFID ORCID Logo  ; Rei, Margarida 6   VIAFID ORCID Logo  ; Kulicke, Corinna 7   VIAFID ORCID Logo  ; Chen, Ji-Li 3 ; Jain, Vitul 8   VIAFID ORCID Logo  ; Woodcock, Victoria K. 3   VIAFID ORCID Logo  ; Colin-York, Huw 3   VIAFID ORCID Logo  ; Hadjinicolaou, Andreas V. 9   VIAFID ORCID Logo  ; Kong, Youxin 8 ; Mayya, Viveka 5 ; Mazet, Julie M. 5   VIAFID ORCID Logo  ; Mead, Gracie-Jennah 5   VIAFID ORCID Logo  ; Bull, Joshua A. 10   VIAFID ORCID Logo  ; Rijal, Pramila 3 ; Pugh, Christopher W. 4   VIAFID ORCID Logo  ; Townsend, Alain R. 3   VIAFID ORCID Logo  ; Gérard, Audrey 5   VIAFID ORCID Logo  ; Olsen, Lars R. 11   VIAFID ORCID Logo  ; Fritzsche, Marco 12 ; Fulga, Tudor A. 13 ; Dustin, Michael L. 5   VIAFID ORCID Logo  ; Jones, E. Yvonne 8   VIAFID ORCID Logo  ; Cerundolo, Vincenzo 3 

 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Southern Denmark, Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Department of Clinical Immunology, Odense University Hospital, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170) 
 University of Oxford, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); CancerCare Manitoba, Paul Albrechtsen Research Institute, Winnipeg, Canada (GRID:grid.419404.c) (ISNI:0000 0001 0701 0170); University of Manitoba, Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609) 
 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, Kennedy Institute of Rheumatology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Universidade de Lisboa, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Lisbon, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263) 
 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oregon Health and Science University, Pulmonary and Critical Care Medicine, Portland, US (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 University of Oxford, Division of Structural Biology, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Cambridge, Division of Gastroenterology & Hepatology, Department of Medicine, Cambridge University Hospitals, Cambridge, England (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Early Cancer Institute, Department of Oncology, Cambridge, England (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934) 
10  Radcliffe Observatory Quarter, Wolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
11  Ørsteds Plads, Department of Health Technology, Technical University of Denmark, Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870) 
12  University of Oxford, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Kennedy Institute of Rheumatology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
13  University of Oxford, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
Pages
3173
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3037674225
Copyright
© The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.